151 material Form 8-K filings that 136 companies we cover made with the SEC in February 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
TG Therapeutics reported fourth quarter and full year 2023 results, furnished as Exhibit 99.1 to a Form 8-K. Full-year total revenue was $233.7 million, including a $140.0 million one-time payment from Neuraxpharm, and the company swung to net income of $12.7 million from a $198.3 million net loss in 2022. The company also set a 2024 BRIUMVI U.S. net product revenue target of $220 million to $260 million, giving shareholders a benchmark for future results.
Q4 2023 total revenue was $44.0 million versus $80 thousand in Q4 2022; Q4 net loss narrowed to $14.4 million from $53.0 million.
Full-year 2023 BRIUMVI U.S. net product revenue was $88.8 million; license, milestone and other revenue was $141.7 million, mainly from the $140.0 million Neuraxpharm payment received in July 2023.
2024 targets: BRIUMVI U.S. net product revenue of approximately $220 million to $260 million and total operating expense of approximately $250 million.
Year-end 2023 cash, cash equivalents and investment securities were $217.5 million.
Valaris reported fourth quarter 2023 results in a press release dated February 21, 2024. Revenue rose to $484 million from $455 million in the third quarter, and net income rose to $829 million, which included a $790 million tax benefit, while the board doubled the share repurchase authorization to $600 million from $300 million.
Net income was $829 million in Q4 2023, up from $17 million in Q3 2023, including a $790 million tax benefit
Revenue rose to $484 million from $455 million; Adjusted EBITDA rose to $58 million from $40 million
Total contract backlog was more than $3.9 billion as of February 15, 2024, and the share repurchase authorization was raised to $600 million from $300 million
National Presto reported 2023 net sales of $340.9 million, up 6.0%, and net earnings of $34.6 million ($4.86 per share), up from $20.7 million ($2.92 per share) in 2022. The Board also declared a 2024 dividend of $1.00 regular plus $3.50 extra per share, and disclosed two Defense segment awards totaling $44.2 million.
Net sales rose to $340.9 million from $321.6 million, led by a $39.2 million increase in Defense segment sales.
Net earnings were $34.6 million ($4.86 per share), compared with $20.7 million ($2.92 per share) in 2022.
2024 dividend is $1.00 regular plus $3.50 extra per share; record date March 1, 2024, payment date March 15, 2024.
Two Defense awards totaling $44.2 million cover 40mm cartridges for Ukraine and Small Diameter Bomb warheads, with completion scheduled for 2024.
Visteon reported fourth-quarter and full-year 2023 results, with full-year net sales of $3.95 billion, up 5%, and record adjusted EBITDA of $434 million. Fourth-quarter net sales fell to $990 million from $1.06 billion, and fourth-quarter net income of $366 million included a $313 million non-cash U.S. tax benefit. The company also guided 2024 sales of $4.0 billion to $4.2 billion and adjusted EBITDA of $470 million to $500 million, and extended CEO Sachin Lawande's employment agreement through September 30, 2030.
Full-year 2023 net sales of $3.95 billion, up 5%; full-year net income of $486 million, or $17.05 per diluted share
Fourth-quarter net sales of $990 million, down from $1,064 million a year earlier, mainly due to lower semiconductor supply recoveries
2024 guidance: sales of $4.0 billion to $4.2 billion, adjusted EBITDA of $470 million to $500 million, adjusted free cash flow of $155 million to $185 million
Employment agreement with CEO Sachin Lawande extended to September 30, 2030; base salary set at $1,150,000 effective April 1, 2024
Doximity reported fiscal third-quarter results for the quarter ended December 31, 2023, with revenue of $135.3 million, up 17%, net income of $48.0 million, up from $33.5 million, and adjusted EBITDA of $73.3 million, up 32%. The company also updated its fiscal 2024 guidance, with full-year revenue now expected between $473.3 million and $474.3 million, and CEO Jeff Tangney called the quarter a "beat and raise" on both top and bottom lines.
Revenue of $135.3 million, versus $115.3 million a year earlier, an increase of 17%.
Net income of $48.0 million, or $0.24 diluted per share, versus $33.5 million, or $0.16, a year earlier.
Fiscal fourth-quarter guidance: revenue of $115.9 million to $116.9 million and adjusted EBITDA of $50.5 million to $51.5 million.
Fiscal 2024 guidance updated to revenue of $473.3 million to $474.3 million and adjusted EBITDA of $224.5 million to $225.5 million.
Qualys reported fourth-quarter and full-year 2023 results that showed revenue and profit growth, and it guided to 2024 revenue growth of 8% to 10%, below the 13% it posted for 2023. The company also raised its share repurchase program by $200 million, which gives shareholders a larger buyback authorization.
Q4 2023 revenue was $144.6 million, up 10% from $130.8 million; GAAP diluted EPS was $1.08 versus $0.74 a year earlier.
Full-year 2023 revenue was $554.5 million, up 13%; GAAP diluted EPS was $4.03 versus $2.74 in 2022.
2024 guidance: revenue of $600 million to $610 million (8% to 10% growth) and non-GAAP diluted EPS of $4.95 to $5.27.
Q4 operating cash flow fell 23% to $33.8 million, and the share repurchase increase is $200 million.
Kirby reported fourth-quarter 2023 net earnings attributable to Kirby of $61.9 million, or $1.04 per diluted share, up from $37.3 million, or $0.62, a year earlier, on revenue of $799.2 million versus $730.2 million. The company also said it expects 2024 earnings to grow 30% to 40% year over year and projected 2024 operating cash flow of $600 million to $700 million, and Chairman Joseph H. Pyne will retire, with Richard J. Alario succeeding him as chairman at the April 26, 2024 annual meeting.
Q4 2023 diluted EPS of $1.04 vs. $0.62 in Q4 2022; revenue of $799.2 million vs. $730.2 million
Full-year 2023 diluted EPS of $3.72 vs. $2.03 in 2022; revenue of $3.1 billion vs. $2.8 billion
2024 outlook: earnings growth of 30% to 40% and operating cash flow of $600 million to $700 million
Joseph H. Pyne retires as chairman; Richard J. Alario becomes chairman effective April 26, 2024
Deckers reported record third-quarter fiscal 2024 results for the quarter ended December 31, 2023, with net sales up 16.0% to $1.560 billion and diluted EPS of $15.11, compared with $10.48 a year earlier. The company raised its full-year fiscal 2024 revenue and diluted EPS guidance, which indicates higher expected profit for shareholders.
Net sales rose 16.0% to $1.560 billion from $1.346 billion; DTC net sales rose 22.7% and wholesale rose 8.6%.
Diluted EPS was $15.11 versus $10.48; gross margin was 58.7% versus 53.0%.
Fiscal 2024 diluted EPS guidance was raised to $26.25 to $26.50, and net sales are now expected to be about $4.15 billion.
The company repurchased about $99.7 million of its stock in the quarter and had about $1.046 billion remaining under its repurchase authorization as of December 31, 2023.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.